Skip to main content

Market Overview

Eli Lilly's Tirzepatide Tops Novo's Semaglutide In Late-Stage Diabetes Study

Share:

Eli Lilly & Co (NYSE: LLY) has reported positive results from another Phase 3 trial evaluating tirzepatide in Type 2 diabetics. The dual GIP/GLP-1 agonist beat Novo Nordisk A/S’s (NYSE: NVO) semaglutide against multiple measures.

  • Recently, Lilly released data from a series of late-phase trials linking tirzepatide to significant reductions in participants’ blood sugar and body weight.
  • The latest readout, from the 1,879-subject, 40-week SURPASS-2 Phase 3 trial, provides evidence that tirzepatide is more effective than the 1-mg dose of Novo’s semaglutide.
  • Across three tirzepatide doses (5 mg, 10 mg, and 15 mg), Lilly saw reductions in A1C, measuring blood sugar, ranging from 2.09% to 2.46%. A1C at baseline was 8.28%. Participants on 1 mg of semaglutide experienced a drop of 1.86% in A1C.
  • The pattern of dose-dependent tirzepatide results, all of which beat semaglutide, was seen across the other endpoints.
  • The proportion of patients with A1C of 5.7% or below, the threshold of normal, in the tirzepatide arms, ranged from 29.3% to 50.9%, compared to 19.7% in semaglutide cohort.
  • Lilly also linked tirzepatide to significant reductions in body weight. Participants on the highest, 15-mg dose of tirzepatide lost 12.4 kg, a 13.1% decline from baseline. Subjects on semaglutide lost 6.2 kg.
  • However, Novo recently linked once-weekly dosing with 2.4 mg of semaglutide to a 14.9% reduction in body weight by Week 68. The available data suggest the higher dose of semaglutide may provide a tougher test for tirzepatide.
  • Semaglutide appears to have a tolerability edge over tirzepatide, too. In the tirzepatide arms, 5.1% to 7.9% of participants stopped treatment due to adverse events. The dropout rate in the semaglutide cohort was 3.8%.
  • Price Action: LLY shares are up 0.7% at $203.44, and NVO shares slipped 1.3% at $70.52 in market trading hours on the last check Thursday.
 

Related Articles (LLY + NVO)

View Comments and Join the Discussion!

Posted-In: Diabetes Phase 3Biotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com